Background: Hepatitis B is a severe overwhelming infection. Hepatitis B is a viral infection that attacks liver cells, causing inflammation and damage to the liver. Infection is usually confined to hepatocytes. Over 2 billion people have been infected with hepatitis B virus at some point. Immunity arises from natural infection or from administration of vaccines. Purpose of the survey: Development of an RNA vaccine against lethal hepatitis B surface antigen of hepatitis B virus.

Research type: screening experiment research. Methodology: In our study, we victimized bioinformatics to engineer an RNA vaccine from hepatitis B surfactant antigen. Lipid nanoparticles with a particle size of 150 nanometers were utilized as a vaccine delivery system. Result: The vaccine has shown an efficacy of 81% in preclinical animal studies and an efficacy of 79% in human clinical studies (Phase 1/2 clinical trials). It exhibited moderate biological activity and had fewer side effects than other standard vaccines. The effect lasted for a long time.

Conclusion:

Our RNA-HBV vaccine was a promising prophylactic vaccine against fatal hepatitis B virus infection.